Login Register Cart 0
Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Monoclonal Antibodies and their Target Specificity Against SARS-CoV-2 Infections: Perspectives and Challenges

Author(s): Mohammed A. Bakkari, Sivakumar Sivagurunathan Moni*, Muhammad Hadi Sultan and Osama A. Madkhali

Volume 16, Issue 1, 2022

Published on: 14 March, 2022

Page: [64 - 78] Pages: 15

DOI: 10.2174/1872208316666220106110014

open access plus

Abstract

The world continues to be in the midst of a distressing pandemic of coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel virus with multiple antigenic systems. The virus enters via nasopharynx, oral and infects cells by the expression of the spike protein, and enters the lungs using the angiotensin-converting enzyme-2 receptor. The spectrum of specific immune responses to SARS-CoV-2 virus infection is increasingly challenging as frequent mutations have been reported and their antigen specificity varies accordingly. The development of monoclonal antibodies (mAbs) will have a more significant advantage in suppressing SARS-CoV-2 virus infectivity. Recently, mAbs have been developed to target included specific neutralizing antibodies against SARS-CoV-2 infection. The use of the therapeutic index of mAbs that can elicit neutralization by binding to the viral spike protein and suppress the cytokine network is a classic therapeutic approach for a potential cure. The development of mAbs against B-cell function as well as inhibition of the cytokine network has also been a focus in recent research. Recent studies have demonstrated the efficacy of mAbs as antibody cocktail preparations against SARS-CoV-2 infection. Target specific therapeutic accomplishment with mAbs, a milestone in the modern therapeutic age, can be used to achieve a specific therapeutic strategy to suppress SARS-CoV-2 virus infection. This review focuses on the molecular aspects of the cytokine network and antibody formation to better understand the development of mAbs against SARS- CoV-2 infection along with recent patents.

Keywords: SARS-CoV-2, immune mechanism, cytokine storm, monoclonal antibodies, neutralizing antibodies, glycoprotein.

« Previous Next »
Graphical Abstract

[1]
El Zowalaty ME, Järhult JD. From SARS to COVID-19: A previously unknown SARS- related coronavirus (SARS-CoV-2) of pandemic potential infecting humans - Call for a One Health approach. One Health 2020; 9(9): 100124.
[http://dx.doi.org/10.1016/j.onehlt.2020.100124] [PMID: 32195311]
[2]
Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. Lancet Infect Dis 2020; 20(7): 773.
[http://dx.doi.org/10.1016/S1473-3099(20)30195-X] [PMID: 32171390]
[3]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[4]
Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. J Med Virol 2020; 92(7): 740-6.
[http://dx.doi.org/10.1002/jmv.25798] [PMID: 32227493]
[5]
Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: A systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther 2021; 28(4): e434-60.
[http://dx.doi.org/10.1097/MJT.0000000000001402] [PMID: 34145166]
[6]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[7]
di Mauro G, Scavone C, Rafaniello C, Rossi F, Capuano A. SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment. Int Immunopharmacol 2020; 84: 106519.
[http://dx.doi.org/10.1016/j.intimp.2020.106519] [PMID: 32311668]
[8]
Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020; 75(7): 1564-81.
[http://dx.doi.org/10.1111/all.14364] [PMID: 32396996]
[9]
Ledford H. Evidence lags behind excitement over blood plasma as a coronavirus treatment. Nature 2020; 584(7822): 505.
[http://dx.doi.org/10.1038/d41586-020-02324-2] [PMID: 32820261]
[10]
Dai L, Wang Q, Qi J, Shi Y, Yan J, Gao GF. Molecular basis of antibody-mediated neutralization and protection against flavivirus. IUBMB Life 2016; 68(10): 783-91.
[http://dx.doi.org/10.1002/iub.1556] [PMID: 27604155]
[11]
Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22(2): 240-73.
[http://dx.doi.org/10.1128/CMR.00046-08] [PMID: 19366914]
[12]
Malkiel S, Barlev AN, Atisha-Fregoso Y, Suurmond J, Diamond B. Plasma cell differentiation pathways in systemic lupus erythematosus. Front Immunol 2018; 9: 427.
[http://dx.doi.org/10.3389/fimmu.2018.00427] [PMID: 29556239]
[13]
Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020; 17(5): 533-5.
[http://dx.doi.org/10.1038/s41423-020-0402-2] [PMID: 32203188]
[14]
Zhang C, Wang XM, Li SR, et al. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 2019; 10(1): 1507.
[http://dx.doi.org/10.1038/s41467-019-09212-y] [PMID: 30944315]
[15]
Masselli E, Vaccarezza M, Carubbi C, et al. NK cells: A double edge sword against SARS-CoV-2. Adv Biol Regul 2020; 77: 100737.
[http://dx.doi.org/10.1016/j.jbior.2020.100737] [PMID: 32773100]
[16]
Li M, Guo W, Dong Y, et al. Elevated exhaustion levels of NK and CD8+ T cells as indicators for progression and prognosis of COVID-19 disease. Front Immunol 2020; 11: 580237.
[http://dx.doi.org/10.3389/fimmu.2020.580237] [PMID: 33154753]
[17]
André P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell 2018; 175(7): 1731-1743.e13.
[http://dx.doi.org/10.1016/j.cell.2018.10.014] [PMID: 30503213]
[18]
Bhaumik S, Basu R. Cellular and molecular dynamics of Th17 differentiation and its developmental plasticity in the intestinal immune response. Front Immunol 2017; 8: 254.
[http://dx.doi.org/10.3389/fimmu.2017.00254] [PMID: 28408906]
[19]
Mendoza VMM. Interleukin-17: A potential therapeutic target in COVID-19. J Infect 2020; 81(2): e136-8.
[http://dx.doi.org/10.1016/j.jinf.2020.05.072] [PMID: 32504739]
[20]
Sivakumar SM, Bremnavas IM. Insights on the application of MATLAB and chaotic principles to determine the targeted delivery of a smart drug delivery system against cancer in the experimental phase: A prospective approach. Asian J Pharm 2020; 14(3): 319-29.
[http://dx.doi.org/10.22377/ajp.v14i03.3680]
[21]
Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (Novel Coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci 2020; 24(4): 2006-11.
[http://dx.doi.org/10.26355/eurrev_202002_20378] [PMID: 32141569]
[22]
Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-ncov) originating in China. Cell Host Microbe 2020; 27(3): 325-8.
[http://dx.doi.org/10.1016/j.chom.2020.02.001] [PMID: 32035028]
[23]
Bestle D, Heindl MR, Limburg H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 2020; 3(9): 2575-1077.
[http://dx.doi.org/10.26508/lsa.202000786] [PMID: 32703818]
[24]
Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 2020; 181(7): 1489-1501.e15.
[http://dx.doi.org/10.1016/j.cell.2020.05.015] [PMID: 32473127]
[25]
Leire de CM, Sonia TV, TP, et al. SARS-CoV-2 sculpts the immune system to induce sustained virus-specific naïve-like and memory B-cell responses. Clin Transl Immunol 2021; 10(9): e1339.
[http://dx.doi.org/10.1002/cti2.1339]
[26]
Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 2020; 587(7833): 270-4.
[http://dx.doi.org/10.1038/s41586-020-2598-9] [PMID: 32726801]
[27]
Magrone T, Magrone M, Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target - A perspective. Endocr Metab Immune Disord Drug Targets 2020; 20(6): 807-11.
[http://dx.doi.org/10.2174/1871530320666200427112902] [PMID: 32338224]
[28]
Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 2020; 16(8): 413-4.
[http://dx.doi.org/10.1038/s41584-020-0448-7] [PMID: 32499548]
[29]
Perrella F, Coppola F, Petrone A, et al. Interference of polydatin/resveratrol in the ACE2: Spike recognition during covid-19 infection. a focus on their potential mechanism of action through computational and biochemical assays. Biomolecules 2021; 11(7): 1048.
[http://dx.doi.org/10.3390/biom11071048] [PMID: 34356672]
[30]
Woelfel R, Victor MC, Wolfgang G, Michael S, Sabine Z, Marcel AM, et al. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel associated transmission cluster. MedRxiv 2020.
[http://dx.doi.org/10.1101/2020.03.05.20030502]
[31]
Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020; 369(6504): 643-50.
[http://dx.doi.org/10.1126/science.abc5902] [PMID: 32540902]
[32]
Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 2020; 368(6496): 1274-8.
[http://dx.doi.org/10.1126/science.abc2241] [PMID: 32404477]
[33]
Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V. Physicochemical stability of monoclonal antibodies: A Review. J Pharm Sci 2020; 109(1): 169-90.
[http://dx.doi.org/10.1016/j.xphs.2019.08.009] [PMID: 31465737]
[34]
Jahanshahlu L, Rezaei N. Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother 2020; 129: 110337.
[http://dx.doi.org/10.1016/j.biopha.2020.110337] [PMID: 32534226]
[35]
Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 2020; 11(1): 2251.
[http://dx.doi.org/10.1038/s41467-020-16256-y] [PMID: 32366817]
[36]
Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020; 2(8): e474-84.
[http://dx.doi.org/10.1016/S2665-9913(20)30173-9] [PMID: 32835257]
[37]
Igawa T. Antibody molecules that bind to IL-6 receptor. US20120253016A1, 2012. Available from:https://patents.google.com/patent/US20120253016A1/en
[38]
Christensen J. CNN health, 2020.. Available from: https://edition.cnn.com/2020/09/29/health/regeneron-covid-19-early-antibody-treatment-results/index.html
[39]
Matthews DB. A cocktail of antibodies for COVID-19 therapy. Nat Rev Immunol 2020; 20(10): 591.
[http://dx.doi.org/10.1038/s41577-020-00431-9] [PMID: 32807860]
[40]
US FDA news release, coronavirus (covid-19) update: FDA authorizes monoclonal antibody for treatment of covid-19. 2020. Available from:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19
[41]
Lescure FX, Honda H, Fowler RA, et al. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo- controlled, phase 3 trial. Lancet Respir Med 2021; 9(5): 522-32.
[http://dx.doi.org/10.1016/S2213-2600(21)00099-0] [PMID: 33676590]
[42]
Stevens S, Huang TT, Martin JH, et al. High affinity antibodies to human IL-6 receptor. US7582298B2, 2009. Available from: https://patents.google.com/patent/US7582298B2/en
[43]
Gritti G, Raimondi F, Ripamonti D, et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support. medRxiv 2020. Available from:https://www.medrxiv.org/content/10.1101/2020.04.01.20048561v1
[44]
Giles-Komar J, Knight D, Peritt D, Trikha M. Anti-IL-6 antibodies, compositions, methods and uses. US7612182B2, 2009. Available from:https://patents.google.com/patent/US7612182B2/en
[45]
US FDA news release, coronavirus (covid-19) update: FDA authorizes monoclonal antibody for treatment of covid-19, November 9th, 2020. 2020. Available from:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19
[46]
Riley GUS. Trial of Lilly antibody therapy to end; no safety issue. 2020. Available from: https://www.bloomberg.com/news/articles/2020-10-26/u-s-run-clinical-trial-of-eli-lilly-antibody-therapy-to-end
[47]
Meredith W. Eli Lilly reports promising first results for an antibody against COVID-19. Science Magazine 2020.
[http://dx.doi.org/10.1126/science.abe8263]
[48]
Robert C. VIR-7831 GSK4182136 is a fully human anti-SARS-CoV-2 monoclonal antibody. 2020. Available from: https://www.precisionvaccinations.com/covid-19-treatment-phase-3-study-expands-globally
[49]
Kempeni , et al. European patent application. 2017. Available from:https://patentimages.storage.googleapis.com/c2/8f/c0/fdf80c38555c63/EP3190124A1.pdf
[50]
Fakharian A, Barati S, Mohamadi M, Dastan F. Successful management of covid-19 with adalimumab in a post-coronary artery bypass graft surgery patient. J Cardiothorac Vasc Anesth 2021; S1053-0770(20)31370-7.
[http://dx.doi.org/10.1053/j.jvca.2020.12.023] [PMID: 33423911]
[51]
Jacobs JJL. Neutralizing antibodies mediate virus-immune pathology of COVID-19. Med Hypotheses 2020; 143: 109884.
[http://dx.doi.org/10.1016/j.mehy.2020.109884] [PMID: 32512289]
[52]
Li Q, Wu J, Nie J, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 2020; 182(5): 1284-1294.e9.
[http://dx.doi.org/10.1016/j.cell.2020.07.012] [PMID: 32730807]
[53]
Robblee J, Collins BE, Kaundinya G, Bosques CJ. Methods related to bevacizumab. US20150147317A1, 2015. Available from: https://patents.google.com/patent/US20150147317A1/en
[54]
Pang J, Xu F, Aondio G, et al. efficacy and tolerability of bevacizumab in patients with severe Covid -19. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.07.26.20159756]
[55]
Robblee J, Collins BD, Kaundinya G, Bosques CJ. Methods related to rituximab.. US Patent 20150141620, 2015. Available from:https://doi.org/patents.google.com/patent/US20150141620
[56]
Dasgupta A, Radford K, Arnold DM, Thabane L, Nair P. The effects of rituximab on serum IgE and BAFF. Allergy Asthma Clin Immunol 2013; 9(1): 39.
[http://dx.doi.org/10.1186/1710-1492-9-39] [PMID: 24219860]
[57]
Polverino F, Seys LJ, Bracke KR, Owen CA. B cells in chronic obstructive pulmonary disease: Moving to center stage. Am J Physiol Lung Cell Mol Physiol 2016; 311(4): L687-95.
[http://dx.doi.org/10.1152/ajplung.00304.2016] [PMID: 27542809]
[58]
Mehta P, Porter JC, Chambers RC, Isenberg DA, Reddy V. B-cell depletion with rituximab in the COVID-19 pandemic: Where do we stand? Lancet Rheumatol 2020; 2(10): e589-90.
[http://dx.doi.org/10.1016/S2665-9913(20)30270-8] [PMID: 33521659]
[59]
Ledford H. The race to make COVID antibody therapies cheaper and more potent. Nature 2020; 587(7832): 18.
[http://dx.doi.org/10.1038/d41586-020-02965-3] [PMID: 33097846]
[60]
Esparza TJ, Martin NP, Anderson GP, Goldman ER, Brody DL. High affinity nanobodies block SARS- CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Sci Rep 2020; 10(1): 22370.
[http://dx.doi.org/10.1038/s41598-020-79036-0] [PMID: 33353972]
[61]
Karen Silence, 2010. Nanobodies for the treatment of aggregation-mediated disorders. . US Patent 20100022452A1, 2010. Available from: https://patents.google.com/patent/US20100022452A1/en
[62]
Piepenbrink MS, Park JG, Oladunni FS, et al. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. BioRxiv 2020.
[http://dx.doi.org/10.1101/2020.10.14.339150]
[63]
Clinical trials, 2020. A phase 2 study of human monoclonal antibodies, BRII-196 and BRII-198. NCT04787211, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04787211
[64]
Jaworski JP. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention. Biomed J 2021; 44(1): 7-17.
[http://dx.doi.org/10.1016/j.bj.2020.11.011] [PMID: 33589377]
[65]
Voors-Pette C, Lebozec K, Dogterom P, et al. Safety and tolerability, pharmacokinetics, and pharmacodynamics of ACT017, an antiplatelet GPVI (glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol 2019; 39(5): 956-64.
[http://dx.doi.org/10.1161/ATVBAHA.118.312314] [PMID: 31017822]
[66]
Renaud L, Lebozec K, Voors-Pette C, et al. Population pharmacokinetic/pharmacodynamic modeling of glenzocimab (ACT017) a Glycoprotein VI inhibitor of collagen-induced platelet aggregation. J Clin Pharmacol 2020; 60(9): 1198-208.
[http://dx.doi.org/10.1002/jcph.1616] [PMID: 32500636]
[67]
ClinicalTrials. Glenzocimab in SARS-Cov-2 Acute Respiratory Distress syndrome Related to COVID-19 (GARDEN). NCT04659109, 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04659109
[68]
Thwaites RS, Sevilla Uruchurtu AS, Siggins M, et al. Elevated antiviral, myeloid and endothelial inflammatory markers in severe COVID-19. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.10.08.20209411]
[69]
ClinicalTrials. Investigating otilimab in patients with severe pulmonary covid-19 related disease (OSCAR). NCT04376684, 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04376684
[70]
Dios Cure Therapeutics. Dios CURE to develop highly specific single-chain antibodies against SARS- CoV-2. 2021. Available from: https://bio.nrw.de/en/dioscure-to-develop-highly-specific-single-chain-antibodies-against-sars-cov-2/
[71]
GSK. 2021. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-us-fda/
[72]
Intrado Global Newswire. GSK and Vir Biotechnology announce sotrovimab (VIR-7831) receives emergency use authorization from the us FDA for treatment of mild-to-moderate covid-19 in high-risk adults and pediatric patients. 2021. Available from: https://www.globenewswire.com/news-release/2021/05/26/2236926/0/en/GSK-and-Vir-Biotechnology-Announce-Sotrovimab-VIR-7831-Receives-Emergency-Use-Authorization-from-the-US-FDA-for-Treatment-of-Mild-to- Moderate-COVID-19-in-High-Risk-Adults-and-Pedia.html
[73]
US FDA. NEWS release FDA authorizes monoclonal antibodies for treatment of COVID-19. Available from:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment- covid-19
[74]
AZD7442. 2020. Available from:https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-long-acting-antibody-laab-combination-azd7442-rapidly-advances-into-phase-iii-clinical-trials.html
[75]
Humanigen Inc, 2021. Lenzilumab significantly improves survival in hospitalised COVID-19 patients. Available from: https://www.europeanpharmaceuticalreview.com/news/149326/lenzilumab-significantly-improves-survival-in-hospitalised-covid-19-patients/
[76]
Burlingame, 2020. Humanigen receives US patent for lenzilumab to treat cytokine storm and neurotoxicity related to CAR-T cell therapy. Available from: http://pharmabiz.com/NewsDetails.aspx?aid=134445&sid=2
[77]
Wenyang Z, Chang Xu, Pingping W, et al. N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation. bioRxiv 2020; 392407.
[http://dx.doi.org/10.1101/2020.11.21.392407]
[78]
Zhang L, Jackson CB, Mou H, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun 2020; 11(1): 6013.
[http://dx.doi.org/10.1038/s41467-020-19808-4] [PMID: 33243994]
[79]
Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019; 4(4): e123158.
[http://dx.doi.org/10.1172/jci.insight.123158] [PMID: 30830861]
[80]
New COVID-19 Variants. CDC: Centres for disease control and prevention, 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html
[81]
Sara R. The U.K. coronavirus mutation is worrying but not terrifying. Sci Am Available from:https://www.scientificamerican.com/article/the-u-k-coronavirus-mutation-is-worrying-but-not-terrifying/
[82]
Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci 2020; 41(11): 815-29.
[http://dx.doi.org/10.1016/j.tips.2020.07.004] [PMID: 32829936]
[83]
Globe Newswire. 2021. Available from: https://www.globenewswire.com/news-release/2021/05/04/2222662/0/en/Monoclonal-Antibodies-MAbS-Global-Market-Report-2021- COVID-19-Impact-and-Recovery-to-2030.html

Rights & Permissions Print Cite
Article Metrics
36
1
© 2024 Bentham Science Publishers | Privacy Policy